FIELD: biotechnologies.
SUBSTANCE: invention can be used in laboratory diagnostics for determination of blood atherogenicity as per level of content of minimum modified lipoproteins of low density (MM-LPLD) in serum or plasma of human blood. MM-LPLD is aggregated from blood serum or plasma by treatment with buffer containing polyvinyl pyrrolidone (PVP) with molar weight of 12600±2700 at final PVP concentration of 11.3% to 14.2% in the sample. After incubation during 10 minutes, light absorption in test and check samples is measured, difference is calculated and at the difference value of more than 10 U blood atherogenicity of the examined person is stated due to increased MM-LPLD level.
EFFECT: use of easy, available and easy-to-implement method of determination of MM-LPLD in human blood allows performing screening investigations in order to determine availability of an atherosclerotic process at a pre-clinical stage and clinical examination of population.
3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD TO DETERMINE ATHEROGENICITY OF HUMAN BLOOD | 2012 |
|
RU2497116C1 |
| METHOD FOR RAPID DETERMINATION OF RESISTANCE TO LDL OXIDATION OF HUMAN SERUM | 2015 |
|
RU2578027C1 |
| METHOD FOR RAPID DETERMINATION OF CHOLESTEROL IN IMMUNE COMPLEXES | 2012 |
|
RU2530627C2 |
| METHOD FOR INSTANT DETERMINATION OF BLOOD ATHEROGENICITY (VERSIONS) | 2010 |
|
RU2437098C1 |
| METHOD FOR SELECTION AND STUDY OF ATHEROGENICITY OF IMMUNE COMPLEXES CONTAINING MULTIPLE MODIFIED LIPOPROTEINS | 2016 |
|
RU2632118C1 |
| MEDIUM AND METHOD FOR DETECTION OF MULTIPLY MODIFIED BLOOD SERUM LIPOPROTEINS | 2010 |
|
RU2444014C1 |
| INSTANT METHOD FOR ASSESSING ATHEROGENICITY OF IMMUNE COMPLEXES OF HUMAN BLOOD SERUM | 2013 |
|
RU2549466C1 |
| METHOD FOR RAPID ANALYSIS OF CHOLESTEROL IN IMMUNE COMPLEXES | 2013 |
|
RU2538685C1 |
| METHOD OF DETERMINATION OF ATHEROGENICITY OF IMMUNE COMPLEXES | 2013 |
|
RU2549467C1 |
| METHOD FOR DETERMINING LYSIS MULTIPLE MODIFIED LOW DENSITY LIPOPROTEIN | 2015 |
|
RU2577719C1 |
